This poster is published under an
open license. Please read the
disclaimer for further details.
Keywords:
Interventional non-vascular, Liver, Oncology, CT, Ablation procedures, Cancer, Metastases, Outcomes
Authors:
S. A. Forbes, C. J. Zagorski, P. E. Jennings, R. Soomal, S. L. Smith; Ipswich/UK
DOI:
10.1594/ecr2014/C-1151
Aims and objectives
Untreated hepatic metastatic disease has a 5 year survival of almost 0% (12).
Current treatment strategies including surgery and interventional radiological techniques such as embolisation and thermal ablation,
have lead to significant improvements in outcomes.
The exact role of these techniques remains a matter of debate.
Surgery carries significant mortality (0-2%) and morbidity (5-16%) rates (14),
with large numbers of patients failing to complete invasive and intensive treatment regimes.
In addition,
only 15-30% of patients are suitable candidates (1),
often as a result of extensive intra- and extra-hepatic disease or associated patient co-morbidities.
Radiofrequency ablation is an image guided,
minimally invasive technique,
which uses a high frequency,
alternating current to cause targeted tissue heating and thermal destruction of tumour cells.
RFA is now emerging as a viable treatment option in selected patients with non-resectable metastatic liver disease.
This single centre study aims to analyse survival,
recurrence and complication rates following RFA of hepatic metastases,
with a view to determining whether RFA can provide comparable outcomes to surgical treatment.